Literature DB >> 25698235

Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Chiranjib Chakraborty1, C George Priya Doss2, Renu Sarin3, Minna J Hsu4, Govindasamy Agoramoorthy5.   

Abstract

In the recent advancement of cancer therapy, mortality of the immortal cancer cells begins to decline, and it shows great promise for the chemotherapy regimen supported by targeted therapy. In this post-genomic era boosted by the discovery of microRNA (miRNA), it has been understood that miRNA regulates gene expression at the post-transcriptional level. On the other hand, some studies have also indicated that miRNA expression level has changed during the treatment of chemotherapy. Data based on various previous studies, we propose that the chemotherapeutic agents modulate miRNA expression that might perform anticancerous activities through cellular changes such as DNA repair, cell cycle arrest, or apoptosis.

Entities:  

Keywords:  Cancer; Gene expression; New hypothesis; Therapy; miRNA

Mesh:

Substances:

Year:  2015        PMID: 25698235     DOI: 10.1007/s00709-015-0776-7

Source DB:  PubMed          Journal:  Protoplasma        ISSN: 0033-183X            Impact factor:   3.356


  63 in total

1.  David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.

Authors:  Brian J Druker
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

2.  MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer.

Authors:  Yi Chen; Mohd Saif Zaman; Guoren Deng; Shahana Majid; Shranjot Saini; Jan Liu; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Cancer Prev Res (Phila)       Date:  2010-11-11

Review 3.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells.

Authors:  Leina Ma; Jia Liu; Junjie Shen; Li Liu; Jia Wu; Wei Li; Jingjing Luo; Qing Chen; Cheng Qian
Journal:  Cancer Biol Ther       Date:  2010-04-01       Impact factor: 4.742

Review 5.  The anticancer effects of resveratrol: modulation of transcription factors.

Authors:  Nichelle C Whitlock; Seung Joon Baek
Journal:  Nutr Cancer       Date:  2012-04-06       Impact factor: 2.900

6.  5-Fluorouracil and oxaliplatin modify the expression profiles of microRNAs in human colon cancer cells in vitro.

Authors:  Jianfeng Zhou; Yanping Zhou; Bin Yin; Wei Hao; Lin Zhao; Wenyi Ju; Chunmei Bai
Journal:  Oncol Rep       Date:  2010-01       Impact factor: 3.906

7.  Resveratrol induces apoptosis of pancreatic cancers cells by inhibiting miR-21 regulation of BCL-2 expression.

Authors:  P Liu; H Liang; Q Xia; P Li; H Kong; P Lei; S Wang; Z Tu
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

8.  Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.

Authors:  Jong-Kook Park; Eun Joo Lee; Christine Esau; Thomas D Schmittgen
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

9.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 10.  Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with a major role in type-2 diabetes.

Authors:  Chiranjib Chakraborty; C George Priya Doss; Sanghamitra Bandyopadhyay; Govindasamy Agoramoorthy
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-06-18       Impact factor: 9.957

View more
  1 in total

Review 1.  The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; Bimal Kumar Sarkar; Sang-Soo Lee
Journal:  Oncotarget       Date:  2018-01-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.